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Background: Slow heart rate recovery (HRR) after exercise is associated with autonomic
dysfunction and increased mortality. What HRR criterion at 1-minute after a 6-minute walk
test (6MWT) best defines pulmonary impairment?.
Study Design and Methods: A total of 5008 phase 2 COPDGene (NCT00608764)
participants with smoking history were included. A total of 2127 had COPD and, of these,
385 were followed-up 5-years later. Lung surgery, transplant, bronchiectasis, atrial fibrilla
tion, heart failure and pacemakers were exclusionary. HR was measured from pulse oximetry
at end-walk and after 1-min seated recovery. A receiver operator characteristic (ROC)
identified optimal HRR cut-off. Generalized linear regression determined HRR association
with spirometry, chest CT, symptoms and exacerbations.
Results: HRR after 6MWT (bt/min) was categorized in quintiles: ≤5 (23.0% of participants), 6–
10 (20.7%), 11–15 (18.9%), 16–22 (18.5%) and ≥23 (18.9%). Compared to HRR≤5, HRR≥11
was associated with (p<0.001): lower pre-walk HR and 1-min post HR; greater end-walk HR;
greater 6MWD; greater FEV1%pred; lower airway wall area and wall thickness. HRR was
positively associated with FEV1%pred and negatively associated with airway wall thickness. An
optimal HRR ≤10 bt/min yielded an area under the ROC curve of 0.62 (95% CI 0.58–0.66) for
identifying FEV1<30%pred. HRR≥11 bt/min was the lowest HRR associated with consistently
less impairment in 6MWT, spirometry and CT variables. In COPD, HRR≤10 bt/min was
associated with (p<0.001): ≥2 exacerbations in the previous year (OR=1.76[1.33–2.34]);
CAT≥10 (OR=1.42[1.18–1.71]); mMRC≥2 (OR=1.42[1.19–1.69]); GOLD 4 (OR=1.98[1.44–
2.73]) and GOLD D (OR=1.51[1.18–1.95]). HRR≤10 bt/min was predicted COPD exacerbations
at 5-year follow-up (RR=1.83[1.07–3.12], P=0.027).
Conclusion: HRR≤10 bt/min after 6MWT in COPD is associated with more severe expiratory
flow limitation, airway wall thickening, worse dyspnoea and quality of life, and future exacer
bations, suggesting that an abnormal HRR≤10 bt/min after a 6MWT may be used in
a comprehensive assessment in COPD for risk of severity, symptoms and future exacerbations.
Keywords: autonomic dysfunction, chest computed tomography, COPD exacerbation,
exercise, spirometry

Background
Chronic obstructive pulmonary disease (COPD) is associated with autonomic
dysfunction1,2 that predicts increased mortality.3,4 Heart rate recovery (HRR) after
exercise is an easily-acquired measure of autonomic dysfunction.5 Abnormal HRR
after maximal exercise, such as a cardiopulmonary exercise test (CPET), predicts
overall mortality in various populations,5–7 and associates with pulmonary function
abnormalities.8 In addition, in COPD, prevalence of impaired HRR increases with
greater GOLD-defined severity of expiratory flow limitation.9
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The 6-minute walk test (6MWT) is a simple test of
functional performance that is used widely in COPD
patient assessment. Six-minute walk distance (6MWD)
associates negatively with COPD hospitalizations, exacer
bations and mortality10 and also predicts survival in
patients with heart failure,11 idiopathic pulmonary
fibrosis12 and pulmonary hypertension.13 Previous studies
used values of ≤12, ≤13, ≤14 or ≤16 bt/min as criterion to
identify abnormal HRR in cardiovascular disease
patients,5,12,14 but a criterion to define a suitable HRR cutoff after 6MWT in COPD is not well established.
A previous study indicated that HRR≤14 bt/min after
a symptom-limited incremental exercise test strongly pre
dicted mortality in 147 COPD patients.7 Rodriguez et al
found, in 101 COPD patients, that HRR≤14 bt/min after
6MWT associated with higher exacerbation risk during the
subsequent 12 months.15 Criteria defining normality in
these studies were based on small sample sizes (<150
COPD patients)7,15 and were not associated with pulmon
ary function or symptoms.15 In COPD, exercise may be
limited by respiratory symptoms prior to reaching cardio
vascular limits, often with substantial heart rate reserve;
therefore, COPD patients with more severe obstruction or
greater symptom burden may exhibit lower HRR follow
ing a 6MWT. Furthermore, autonomic function may be
associated with changes that affect vagal afferent innerva
tion of the respiratory tract16,17 reflected in anatomic chest
CT variables. Establishing a criterion HRR following
6MWT in COPD that is associated with lung function,
dyspnoea and quality of life and future exacerbations (as
opposed to cut-offs established in other disease states or
testing modalities) has the potential to provide insight into
health status and guide management. We therefore aimed
to identify an HRR abnormality criterion after 6MWT that
associated independently with COPD, COPD severity,
symptoms, and predicted future exacerbations. To achieve
this, we analysed data from the longitudinal cohort study,
the Genetic Epidemiology of COPD (COPDGene).

Methods
Study Design and Population
This was a retrospective analysis of COPDGene18
(NCT00608764) participants at 5 years (phase 2; 2012–
2017) and 10 years (Phase 3; 2017–2019) after their initial
study visit. The 5-year visit was the first visit at which
HRR was recorded. COPDGene enrolled current and for
mer smokers with ≥10 pack-years smoking history and
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never smokers. Participants were either Non-Hispanic
White or African American and aged 45–90 years at
their 5-year visit. A detailed description of the study
design and inclusion/exclusion criteria is available.18
Those with complete 6MWT and lung function data were
included in the analysis and those with lung surgery,
transplant, bronchiectasis, atrial fibrillation, heart failure,
and pacemakers were excluded. Participants underwent
6MWT, post-bronchodilator spirometry, quantitative com
puted tomography (CT), and questionnaires to assess
symptoms and medical history. The COPDGene protocol
was approved by institutional review boards at 21 partici
pating centres (see online supplement) and conducted in
accordance with the Declaration of Helsinki. Written
informed consent was obtained from all participants.

Measurements
6MWT was performed at all sites according to ATS
guidelines19 and as described in the COPDGene manual
of procedures. Heart rate and SpO2 were measured using
a pulse oximeter after 10 minutes of seated rest prior to the
walk, immediately at walk’s end, and 1-minute after the
end of the walk. At the end of the walk, participants were
seated as quickly but as safely as possible. HRR (indepen
dent variable) was defined as the difference in HR between
end-walk and 1-min recovery. HRR grades were identified
according to quintiles of HRR: HRR≤5 bt/min, 6–10 bt/
min, 11–15 bt/min, 16–22 bt/min and HRR ≥23 bt/min.
Exposures included smoking history, exacerbation his
tory, and medication use. Outcome variables included the
scores of the modified Medical Research Council dys
pnoea questionnaire (mMRC) and COPD assessment test
(CAT). Exacerbation frequency during the year prior to the
5-year or 10-year follow-up visits, with exacerbation
defined as acute worsening of COPD symptoms that
resulted either in prescription of a course of antibiotics
or oral corticosteroids, or in hospitalization (ie, moderate
or severe exacerbations).20 Frequent exacerbations were
defined as ≥2 exacerbations in the previous year.20,21
Outcomes also included COPD severity, assessed by
GOLD spirometric stage, and COPD Group by assessment
of symptoms and risk of exacerbations based on the 2020
GOLD guidelines, eg GOLD group D were those with
mMRC ≥2 or CAT ≥10 and exacerbation frequency ≥2
in the previous year.20
Spirometry was performed using an EasyOne®
Spirometer (ndd, Zurich, Switzerland) before and after
administration of a short-acting β2-agonist (albuterol)
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according to ATS/ERS recommendations.22 Spirometry
studies were reviewed centrally by COPDGene to ensure
multicentre quality control.18 The greatest combined FEV1
and FVC measurements of three acceptable efforts was
reported. Lung diffusing capacity for carbon monoxide
(DLCO) was measured by using the EasyOne Pro system
(ndd Medical Technologies, Inc.) in accordance with
European Respiratory Society/American Thoracic Society
standards for measurement of single-breath carbon mon
oxide uptake in the lung.23 DLCO percent predicted values
were calculated by using Global Lung Initiative reference
equations,24 with DLCO values adjusted for haemoglobin
and altitude.
Exploratory outcomes included CT scans variables. CT
scan at phase 2 COPDGene were performed at full inspira
tion (200 mAs), and at the end of normal expiration (50
mAs).18 Airway wall thickening was assessed by segmen
tal airway wall thickness (AWT) calculated as average
values in six segmental bronchi, segmental wall area per
centage (WA%=[outer bronchus area-airway luminal
area]/outer bronchus area×100) obtained at the same sites
as used for airway wall thickness, and the square root of
wall area of a 10-mm perimeter airway (Pi10).25–27
Emphysema percentage was defined as percentage of
lung voxels ≤−950 Hounsfield units (HU) on an endinspiratory CT scan, and gas trapping percentage was
defined as percentage of lung voxels ≤−856 HU on expira
tory CT.27,28

Statistical Analyses
Data are presented as mean±SD, median (interquartile
range) or number (percent). Univariate analyses were per
formed using one-way ANOVA, Kruskal–Wallis tests,
independent-samples Student’s t or Mann–Whitney test
for continuous variables and chi-square test or z-test for
proportions, as appropriate. Associations between HRR or
HRR quintile (independent variables) and pulmonary func
tion and quantitative CT (dependent variables) were
assessed by multivariable generalized linear regression
models. Emphysema percentage and gas trapping percen
tage were natural log transformed to account for skewed
distributions. Estimates of linear trend across increasing
HRR quintiles were performed by including median of
each quintile as a continuous variable (providing a P-fortrend value). The optimal HRR cut-off point (highest sum
of sensitivity and specificity) to identify FEV1<30%pred
was selected using receiver operating characteristic (ROC)
analysis. Relationships between HRR cut-off (independent
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variable) and exacerbations and symptoms (dependent
variables) were assessed by logistic regression models.
At the 5-year visit (phase 2) relationships between HRR
and exacerbation frequency ≥2 in the previous year, CAT
≥10 and mMRC ≥2 were assessed. COPD patients with
available data were followed-up at the 10-year visit
(phase 3), where the relationship between HRR at phase
2 and exacerbations in the year prior to phase 3 was
assessed. Multivariable models were adjusted for race,
sex, age, body mass index (BMI), smoking history, cardi
ovascular disease (CVD) history and (for CT measures)
CT scanner type. All statistical analyses were performed
using SPSS (IBM SPSS V.25.0, Armonk, NY, USA).
Alpha level was set at P<0.05, with Bonferroni correction
where needed to account for multiple comparisons.
Figures were created using GraphPad Software
(GraphPad Prism V.8.0 for Windows, San Diego,
California USA).

Results
Subject Characteristics
10,311 non-Hispanic white and African American partici
pants were initially enrolled in COPDGene (phase 1). Of
these, 6758 were followed-up at phase 2 (5-year visit). Of
those, 1750 were excluded from this analysis (Figure 1):
876 of these did not conduct 6MWT or spirometry; and
874 were excluded on the basis of history of other lung
disease including interstitial lung disease (ILD) and
bronchiectasis, or history of heart disease including atrial
fibrillation and heart failure, or previous lung resection or
being a never-smoker. 5008 participants were included for
analysis, of whom 2127 (42.5%) had COPD, 627 had
preserved ratio with impaired spirometry (PRISm), and
2254 had normal spirometry. 385 of the COPD patients
with 5.5±0.5 years of follow-up duration were also
assessed at the 10-year visit of COPDGene. The remaining
participants had either not yet reached their 10-year visit
date or were lost to follow-up.
To identify variables associated the HRR across the
whole cohort, we compared HRR characteristics with the
reference group of HRR ≤5 bt/min (Table 1). Compared
with HRR ≤5 bt/min, individuals with 6≤HRR≤10 bt/min
had greater 6MWD, BMI, end-walk HR and DLCO%pred
and slightly lower Pi10 from quantitative CT (Table 1).
However, spirometry, and most other 6MWT- and CTrelated variables were not statistically different between
the first 2 quintiles of HRR (Table 1).
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6,758 participants at their 5-year (phase 2)
visit of COPDGene
1,750 excluded:
827 without 6MWT
49 without spirometry
28 history of other lung disease including
ILD and bronchiectasis
300 history of heart disease including atrial
fibrillation and heart failure
131 previous lung resection
415 never smokers
5,008 participants at phase 2 COPDGene
2,127 with COPD
627 with PRISm
2,254 with normal spirometry

HRR 5
n=1,151

10<HRR 15
n=946

15<HRR 22
n=926

HRR 23
n=949

4,623 excluded:
627 with PRISm
2,254 with normal spirometry
1,742 with COPD but without 10-year followup data
385 COPD patients at their 10-year (phase 3)
visit of COPDGene
Figure 1 Study design.
Abbreviation: PRISm, Preserved Ratio Impaired Spirometry defined as FEV1/FVC≥70% but FEV1<80%.

However, participants in the 3rd quintile (11≤HRR≤15
bt/min) had many variables that were significantly differ
ent from reference (HRR≤5 bt/min). Those with HRR≥11
bt/min were older, with greater BMI and 6MWD, lower
pre-walk HR and 1-min post HR, greater end-walk HR and
SpO2, less impaired spirometry (FEV1%pred, FEV1/FVC),
greater DLCO%pred, less gas trapping, Pi10 and airway
wall thickness. Therefore, 6MWT, spirometry and CT
variables were significantly less impaired in participants
at HRR≥11 bt/min compared with those in the first two
quintiles. Above this quintile, there were few additional
significant findings: greater pack-years smoking, greater
pre-walk and end-walk SpO2, greater FVC%pred and
lower airway wall thickness (at HRR≥16 bt/min), and
less emphysema (at HRR≥23 bt/min). In ROC analysis,
an optimal HRR≤10 beat/min yielded an area under the
curve (AUC) of 0.62 (95% CI 0.58–0.66) for identifying
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FEV1<30%pred. This cut-off corresponded to a sensitivity
of 62% and specificity of 58%. Overall, in smokers with
and without COPD, HRR≥11 bt/min was the lowest HRR
associated with consistently less impairment in 6MWT,
spirometry and CT variables.

Spirometry, Chest CT and HRR
Associations between measures of pulmonary function and
HRR in the whole cohort were further assessed by multi
variable generalized linear regression models, adjusted for
age, sex, race, BMI, smoking status and cardiovascular dis
ease history. When modelled as a continuous variable, HRR
was independently associated with spirometry (Table 2). In
categorical analyses, compared with HRR≤5 bt/min, pul
monary function variables (FEV1%pred, FVC%pred, FEV1
/FVC and DLCO%pred) were greater (each P<0.001) when
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28.1±6.2
674 (58.6%)

BMI (kg/m2)
Race, Non-Hispanic White, n (%)

535 (46.5%)
46±25

Current smoker
Smoking (pack-years)
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70.5±22.0
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Emphysema (%)

1.8 (0.5–6.8)

66.3±15.2

Post-BD FEV1/FVC (%)

DLCO%pred (%)

Quantitative chest CT

75.6±24.6
85.8±17.7

Post-BD FEV1%pred (%)
Post-BD FVC%pred (%)

Pulmonary function

86±17
87±17
93.2±6.2

HR end-of-walk (bt/min)

HR 1-min post (bt/min)
SpO2 end-of-walk (%)

75±13
96.0±3.3

HR pre-walk (bt/min)
SpO2 pre-walk (%)

6MWD (m)

362.9±118.8

603 (52.4%)
214 (18.6%)

Hypertension
Diabetes

6-min walk test

171 (14.9%)

Cardiovascular disease

Comorbidities, n (% of quintile)

616 (53.5%)

Former smoker

Smoking status, n (% of quintile)

613 (53.3%)

64.3±8.8

1151 (23.0%)

HRR≤5

Sex Male, n (% of quintile)

Age (years)

Demographics

N (% of total)

Variables

1.8 (0.5–5.9)

74.5±21.1*

66.9±15.5

76.9±24.9
86.0±17.6

95.9±3.5

86±16
93.6±5.0

94±16*

74±12
96.0±2.9

388.5±113.8*

566 (54.6%)
209 (20.2%)

135 (13.0%)

432 (41.7%)
44±23

604 (58.3%)

29.2±6.3*
730 (70.5%)*

530 (51.2%)

65.6±8.5*

1036 (20.7%)

6≤HRR≤10

1.6 (0.5–5.1)

77.2±21.6*

68.3±14.3*

79.8±23.9*
87.7±17.4

96.1±3.4*

85±15*
93.8±5.2

98±16*

73±12*
96.1±2.6

412.0±111.0*

471 (49.8%)
150 (15.9%)

133 (14.1%)

349 (36.9%)*
43±23

597 (63.1%)*

29.1±6.1*
712 (75.3%)*

482 (51.0%)

65.5±8.4*

946 (18.9%)

11≤HRR≤15

Table 1 Baseline Participant Characteristics in Quintiles of Heart Rate Recovery (HRR, bt/min)

1.5 (0.5–4.7)

76.9±20.5*

69.1±13.4*

80.7±22.9*
88.2±17.3*

96.6±3.1*

83±15*
94.1±5.1*

102±15*

73±12*
96.4±2.3*

425.2±114.0*

440 (47.5%)
159 (17.2%)

102 (11.0%)*

359 (38.8%)*
42±22*

567 (61.2%)*

29.3±6.4*
668 (72.1%)*

437 (47.2%)*

64.6±8.5

926 (18.5%)

16≤HRR≤22

1.2 (0.3–3.6)*

77.2±21.1*

70.0±13.2*

83.9±22.6*
90.9±17.1*

96.8±2.8*

79±15*
93.1±6.2

112±16*

71±11*
96.5±2.6*

446.0±124.8*

427 (45.0%)*
122 (12.9%)*

80 (8.4%)*

355 (37.4%)*
40±21*

594 (62.6%)*

29.0±6.6*
639 (67.3%)*

447 (47.1%)*

64.0±8.2

949 (18.9%)

HRR≥23

1.5 (0.4–5.2)

75.1±21.4

68.0±14.5

79.2±24.0
87.6±17.5

96.2±3.5

84±16
93.5±5.6

98±18

73±12
96.2±2.8

404.7±120.2

2507 (50.1%)
854 (17.1%)

621 (12.4%)

2030 (40.5%)
43±23

2978 (59.5%)

28.9±6.3
3423 (68.4%)

2509 (50.1%)

64.8±8.5

5008

Total

<0.001

<0.001

<0.001

<0.001
<0.001

<0.001

<0.001
0.001

<0.001

<0.001
<0.001

<0.001

<0.001
<0.001

<0.001

<0.001
<0.001

<0.001

<0.001
<0.001

0.018

<0.001

–

P value

(Continued)
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1.06±0.23

AWT (mm)

1.05±0.22

2.28±0.57*
50.6±8.2

14.3 (5.7–28.0)

6≤HRR≤10

1.03±0.22

2.24±0.57*
49.9±8.4*

12.9 (6.3–27.9)*

11≤HRR≤15

1.01±0.21*

2.22±0.53*
49.3±8.1*

12.5 (5.5–28.0)*

16≤HRR≤22

0.99±0.21*

2.20±0.55*
48.8±8.3*

12.1 (5.3–23.2)*

HRR≥23

1.03±0.22

2.27±0.57
50.0±8.4

13.5 (5.9–28.4)

Total

<0.001

<0.001
<0.001

<0.001

P value

β (95% CI) HRR as

0 (ref)
0 (ref)
0 (ref)

−0.001 (−0.003 to 0.001)

−0.002 (−0.004 to −0.001)#

−0.043 (−0.060 to −0.026)#

Ln gas trapping (%)

Pi10 (mm)

WA (%)

−0.015 (−0.031 to 0.001)

−0.599 (−1.257 to 0.059)

−0.066 (−0.113 to −0.019) *

−0.023 (−0.039 to −0.006)*

−1.047 (−1.727 to −0.366)*

−0.084 (−0.132 to −0.036)*

−0.015 (−0.103 to 0.073)

0.017 (−0.121 to 0.154)

−0.015 (−0.148 to 0.118)
−0.041 (−0.127 to 0.044)

4.614 (2.787 to 6.441)#

2.310 (1.140 to 3.480)#

2.492 (1.015 to 3.969)

#

4.684 (2.638 to 6.730)#

11≤HRR≤15 (n=946)

2.605 (0.828 to 4.382)*

0.861 (−0.279 to 2.000)

0.756 (−0.682 to 2.194)

1.772 (−0.219 to 3.764)

6≤HRR≤10 (n=1036)

−0.039 (−0.056 to −0.021)

#

−1.611 (−2.298 to −0.923)#

−0.110 (−0.159 to −0.061)#

−0.073 (−0.163 to 0.017)

0.075 (−0.064 to 0.213)

4.062 (2.235 to 5.889)#

2.471 (1.294 to 3.648)#

2.998 (1.512 to 4.483)

#

5.159 (3.101 to 7.217)#

16≤HRR≤22 (n=926)

Mean Difference (95% CI) by Quintile of HRR

−0.042 (−0.060 to −0.025)#

−1.723 (−2.420 to −1.026)#

−0.121 (−0.171 to −0.072)#

−0.068 (−0.159 to 0.023)

0.010 (−0.130 to 0.151)

4.503 (2.695 to 6.310)#

3.153 (1.985 to 4.322)#

5.372 (3.898 to 6.846)#

7.984 (5.942 to 10.027)#

HRR≥23 (n=949)

P for

<0.001

<0.001

<0.001

0.124

0.618

<0.001

<0.001

<0.001

<0.001

Trend

Notes: Data are presented as Mean difference (95% CI). Emphysema percentage and gas trapping percentage were natural log (Ln) transformed to account for their skewed distributions. *P<0.05, #P<0.001, assessed by multivariate
generalized linear regression models adjusted for age, sex, race, BMI, smoking status, CVD history, and CT scanner type for CT outcomes. P for trend were estimated by generalized linear models including the median of each quartile as
a continuous variable.
Abbreviations: HRR, heart rate recovery; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide; DLCO%pred, percentage of predicted DLCO, adjusted for
haemoglobin concentration and altitude; CT, computed tomography; Pi10, square root wall area of a 10-mm perimeter airway; WA, segmental wall area percentage; AWT, segmental airway wall thickness.

−0.001 (−0.001 to −0.001)
0 (ref)

0 (ref)

0.002 (−0.002 to 0.005)

Ln emphysema (%)

AWT (mm)

0 (ref)

0.096 (0.051 to 0.141)#

DLCO%pred (%)

#

0 (ref)

0.070 (0.041 to 0.099)#

FEV1/FVC (%)

0 (ref)

0 (ref)

HRR≤5 (n=1151)

0.134 (0.097 to 0.171)

#

0.187 (0.136 to 0.238)#

a Continuous Variable

FVC%pred

FEV1%pred

Dependent Variables

Table 2 Adjusted Associations Among Pulmonary Function, Quantitative CT and Heart Rate Recovery (HRR, bt/min)

Notes: Data are presented as mean±SD or median (25th and 75th percentiles), or number (percent). *P<0.05 (with Bonferroni correction) for comparison with individuals with HRR≤5 bt/min, obtained from one-way ANOVA or
Kruskal–Wallis tests or z-test (for proportions).
Abbreviations: HRR, heart rate recovery; BMI, body mass index; SpO2, oxygen saturation by pulse oximeter; 6MWD, 6-minute walk distance; BD, bronchodilator; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity;
DLCO, diffusing capacity of the lungs for carbon monoxide; DLCO%pred, percentage of predicted DLCO, adjusted for haemoglobin concentration and altitude; CT, computed tomography; Pi10, square root wall area of a 10-mm perimeter
airway; WA, segmental wall area percentage; AWT, segmental airway wall thickness.

2.36±0.62
51.2±8.6

16.3 (6.9–32.9)

HRR≤5

Pi10 (mm)
WA (%)

Gas trapping (%)

Variables

Table 1 (Continued).
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HRR≥11 bt/min, and increased progressively across HRR
quintiles above this level (each P for trend <0.001) (Table 2).
To identify the locus of these associations we per
formed a sub-group analysis of HRR in COPD, PRISm
and normal spirometry. We found that the associations
were driven largely by the COPD group, because there
were no consistent associations between HRR quintiles
and pulmonary function variables in PRISm and normal
spirometry groups, assessed separately (Table 3). Only
FVC%pred was weakly associated (β = 0.043, 95% CI =
0.008 to 0.079) with HRR as a continuous variable in
normal spirometry smokers. In the COPD sub-group, how
ever, all pulmonary function variables were significantly
associated with HRR considered as a continuous variable,
or as a trend across quintiles (P<0.05) (Table 3).
We also aimed to explore associations between pul
monary morphology measured by quantitative CT, and
HRR in the whole cohort. Multivariable generalized lin
ear regression models were adjusted for age, sex, race,
BMI, smoking status, cardiovascular disease history, and
CT scanner type. Using HRR as a continuous variable,
HRR was independently negatively associated with wall
area percentage, airway wall thickness and Pi10 (each
P<0.001) but not with emphysema or gas trapping
(Table 2). This association was also observed in catego
rical analyses, with wall area percentage, airway wall
thickness and Pi10 being consistently less impaired at
HRR≥11 bt/min compared with reference (HRR≤5 bt/
min; each P<0.05; Table 2). There was progressive
decrease in wall area percentage, airway wall thickness
and Pi10 with increase in HRR quintile (each P for trend
<0.001), but not with emphysema or gas trapping (each
P for trend >0.124; Table 2). These findings were again
corroborated in subgroup analysis (Table 3) where, in
COPD patients, wall area percentage, airway wall thick
ness and Pi10, but not emphysema or gas trapping, were
associated with HRR when HRR was considered as
continuous or as categorical variable with HRR≥6 bt/
min. Wall area percentage and airway wall thickness
were significantly negatively associated with HRR as
continuous variable in PRISm subjects, however these
associations were extremely weak (β < −0.022; Table 3).

COPD Symptoms, Severity and HRR
Finding significant associations between HRR and ana
tomic and functional variables in the COPD sub-group,
we then assessed associations with COPD symptoms.
Multivariable logistic regression models were adjusted
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for age, sex, race, BMI, smoking status and cardiovascular
disease history. When HRR was modelled as a continuous
variable, HRR was independently associated with severe
symptoms and exacerbation frequency ≥2 (Table 4). In
categorical analyses, compared with HRR≤5 bt/min, odds
ratios (ORs) of severe symptoms were decreased (each
P<0.05) when HRR≥11 bt/min, and decreased progres
sively across HRR quintiles above this level (each P for
trend <0.001) (Table 4).
In univariable and multivariable analyses, significant
differences among 6MWT, pulmonary function and CT
variables in COPD patients were first observed at
HRR≥11 bt/min. We therefore explored the association
between HRR≤10 bt/min and COPD severity. After
adjusting for age, sex, race, BMI, smoking status and
cardiovascular disease history, HRR≤10 bt/min was
independently associated (P<0.001) with: Exacerbation
frequency ≥2 in the previous year (OR=1.76[1.33–
2.34]); CAT ≥10 (OR=1.42[1.18–1.71]); and mMRC ≥2
(OR=1.42[1.19–1.69]) (Figure 2A). Compared to those
with HRR≥11 bt/min, COPD patients with HRR≤10 bt/
min had 1.97 times the risk of very severe obstruction
(OR for GOLD 4 =1.98[1.44–2.73]) and 1.51 times the
risk of having worse symptoms combined with ≥2
exacerbations in the previous year (OR for GOLD
D=1.51[1.18–1.95]) (Figure 2B).

HRR Predicts Exacerbations at 5-Years
We then assessed the prognostic value of HRR 10≤bt/min
for future exacerbations. Logistic regression models
assessed association between HRR≤10 bt/min and exacer
bations in the year preceding the phase 3 visit in 385
COPD patients. Risk ratios (RR) of future exacerbations
predicted by abnormal HRR are presented in Table 5. RR
was essentially constant in the crude model, and across 5
models adjusting for a range of variables (Table 5). After
adjusting for sex, age, BMI, race, smoking status, cardio
vascular disease history, FEV1%pred, DLCO%pred and
6MWD, HRR≤10 bt/min was associated with exacerba
tions risk ratio (RR=1.83[1.07–3.12], P=0.027) (Table 5).

COPD Characteristics Stratified by HRR
Having identified an optimal cut-off of HRR≤10 bt/min
was associated with airway morphology, disease severity,
dyspnoea, quality of life, exacerbation frequency and risk
of future exacerbations in COPD, we compared the char
acteristics of COPD patients at phase 2 (n=2127) with
HRR≤10 bt/min and ≥11 bt/min. Compared with COPD
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0 (ref)

0 (ref)
0 (ref)
0 (ref)
0 (ref)
0 (ref)

0.172 (0.107 to 0.237)#

0.070 (0.041 to 0.108)*

0.124 (0.051 to 0.198)*

0.001 (−0.004 to 0.006)

−0.002 (−0.004 to 0.001)

−0.002 (−0.004 to −0.000)*

−0.045 (−0.072 to −0.018)*

−0.001 (−0.002 to −0.001)#

FVC%pred (%)

FEV1/FVC (%)

DLCO%pred (%)

Ln emphysema (%)

Ln gas trapping (%)

Pi10 (mm)

WA (%)

AWT (mm)

0 (ref)
0 (ref)
0 (ref)

0 (ref)
0 (ref)

0.002 (−0.051 to 0.056)

0.000 (−0.031 to 0.030)

−0.039 (−0.153 to 0.074)

0.008 (−0.002 to 0.017)

0.005 (−0.001 to 0.011)

0.002 (−0.001 to 0.005)

−0.007 (−0.055 to 0.040)

0.000 (−0.001 to 0.002)

FVC%pred (%)

FEV1/FVC (%)

DLCO%pred (%)

Ln emphysema (%)

Ln gas trapping (%)

Pi10 (mm)

WA (%)

AWT (mm)
(n=442)

0 (ref)

FEV1%pred (%)

0 (ref)

0 (ref)

Normal Spirometry
Participants

0.029 (−0.007 to 0.065)

0 (ref)

0.003 (−0.045 to 0.051)

FEV1%pred (%)
0 (ref)

(n=161)

PRISm Patients

0 (ref)

0 (ref)

0 (ref)

(n=548)

HRR≤5

0.199 (0.124 to 0.274)#

β (95% CI) HRR as
a Continuous Variable

FEV1%pred (%)

COPD Patients

Dependent Variables

0.353 (−1.183 to 1.890)

(n=430)

0.042 (−0.003 to 0.086)

1.485 (−0.223 to 3.192)

0.467 (−1.058 to 1.993)

(n=449)

0.027 (−0.020 to 0.075)

0.655 (−1.158 to 2.467)

0.034 (−0.087 to 0.156)

−0.070 (−0.292 to 0.152)

−0.083 (−0.297 to 0.131)
0.055 (−0.060 to 0.169)

0.016 (−0.334 to 0.367)

−0.523 (−1.691 to 0.645)

−0.153 (−1.285 to 0.979)

−0.059 (−0.389 to 0.272)

−0.665 (−2.705 to 1.375)

−0.526 (−2.503 to 1.451)

2.976 (−1.192 to 7.143)

−1.100 (−2.947 to 0.746)

−0.674 (−2.464 to 1.116)

−0.139 (−4.211 to 3.932)

(n=118)

−0.027 (−0.054 to −0.000)

−0.546 (−1.565 to 0.474)

−0.025 (−0.100 to 0.050)

(n=127)

−0.036 (−0.061 to −0.011)*

−1.187 (−2.135 to −0.239)*

−0.095 (−0.164 to −0.025)*

0.030 (−0.069 to 0.128)

0.099 (−0.077 to 0.275)

−0.019 (−0.183 to 0.145)
−0.004 (−0.097 to 0.088)

3.900 (1.015 to 6.786)*

0.513 (−1.032 to 2.058)

−0.340 (−1.786 to 1.106)
3.684 (0.987 to 6.380)*

2.136 (−0.384 to 4.657)

2.202 (−0.699 to 5.102)

(n=379)

11≤HRR≤15

0.755 (−1.605 to 3.115)

0.484 (−2.231 to 3.199)

(n=479)

6≤HRR≤10

0.671 (−0.856 to 2.207)

1.093 (−0.391 to 2.085)

(n=497)

0.015 (−0.034 to 0.065)

−0.004 (−0.052 to 0.043)
(n=436)

0.442 (−1.462 to 2.346)

0.069 (−0.058 to 0.196)

0.127 (−0.114 to 0.367)

0.224 (−0.143 to 0.591)

−1.007 (−5.311 to 3.298)

0.136 (−1.065 to 1.337)

0.378 (−1.719 to 2.476)

0.560 (−1.339 to 2.458)

(n=104)

−0.062 (−0.091 to −0.034)#

−2.162 (−3.241 to −1.084)

#

−0.137 (−0.217 to −0.058)*

−0.114 (−0.220 to −0.008)*

−0.014 (−0.200 to 0.172)

5.554 (2.633 to 8.474)

#

2.524 (0.940 to 4.108)*

6.677 (4.091 to 9.262)#

7.675 (4.701 to 10.650)#

(n=348)

HRR≥23

−0.308 (−2.124 to 1.508)

0.014 (−0.108 to 0.135)

0.001 (−0.224 to 0.227)

0.388 (0.037 to 0.739) *

3.339 (−0.785 to 7.464)

−0.104 (−1.260 to 1.052)

0.329 (−1.690 to 2.348)

0.124 (−1.704 to 1.952)

(n=117)

−0.048 (−0.075 to −0.020)*

−1.698 (−2.740 to −0.655)*

−0.104 (−0.180 to 0.027)*

0.001 (−0.102 to 0.103)

0.090 (−0.090 to 0.270)

3.556 (0.704 to 6.429)*

1.707 (0.155 to 3.259)*

3.460 (0.927 to 5.992)*

4.248 (1.334 to 7.162)*

(n=373)

16≤HRR≤22

Mean Difference (95% CI) by Quintile of HRR

0.134

0.935

0.813

0.452

0.245

0.050

0.868

0.815

0.534

0.405

<0.001

<0.001

0.002

0.054

0.810

0.001

<0.001

<0.001

<0.001

P for
Trend

Table 3 Adjusted Associations Among Pulmonary Function, Quantitative CT and Heart Rate Recovery (HRR, bt/min) in Subgroups: Patients with COPD, PRISm and Normal
Spirometry
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0 (ref)

0 (ref)
0 (ref)
0 (ref)
0 (ref)

−0.011 (−0.026 to 0.004)

0.015 (−0.035 to 0.065)

0.006 (0.002 to 0.010)*

0.002 (−0.001 to 0.005)

−0.001 (−0.002 to 0.000)

−0.022 (−0.043 to −0.001)*

−0.001 (−0.001 to 0.000)*

FEV1/FVC (%)

DLCO%pred (%)

Ln emphysema (%)

Ln gas trapping (%)

Pi10 (mm)

WA (%)

AWT (mm)

0.000 (−0.022 to 0.022)

−0.242 (−1.112 to 0.628)
−0.007 (−0.029 to 0.015)

−0.679 (−1.544 to 0.186)

−0.048 (−0.099 to 0.002)

0.122 (0.004 to 0.241) *

−0.062 (−0.180 to 0.056)
−0.038 (−0.088 to 0.013)

0.163 (−0.005 to 0.331)

1.073 (−1.055 to 3.201)

−0.137 (−2.272 to 1.998)
0.029 (−0.140 to 0.198)

0.178 (−0.448 to 0.805)

0.273 (−1.212 to 1.758)

0.852 (0.220 to 1.483)*

−0.651 (−2.147 to 0.846)

−0.020 (−0.042 to 0.002)

−0.928 (−1.796 to −0.061)*

−0.056 (−0.107 to −0.005)*

−0.003 (−0.122 to 0.115)

0.186 (0.018 to 0.355)*

0.859 (−1.279 to 2.998)

0.219 (−0.413 to 0.850)

0.386 (−1.110 to 1.882)

−0.015 (−0.037 to 0.007)

−0.622 (−1.480 to 0.236)

−0.041 (−0.091 to 0.010)

0.088 (−0.029 to 0.205)

0.219 (0.052 to 0.386)*

0.076 (−1.981 to 2.133)

−0.130 (−0.740 to 0.479)

1.298 (−0.146 to 2.743)

0.075

0.099

0.151

0.080

0.004

0.838

0.145

0.020
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OR (95% CI) HRR as

0.985 (0.977 to 0.992)#

CAT ≥ 10

1 (reference)

1 (reference)

1 (reference)

HRR≤5 (n=548)

0.832 (0.633 to 1.094)

0.844 (0.653 to 1.091)

1.043 (0.732 to 1.504)

6≤HRR≤10 (n=479)

0.718 (0.540 to 0.957)*

0.667 (0.508 to 0.876)*

0.613 (0.394 to 0.955)*

11≤HRR≤15 (n=379)

0.650 (0.487 to 0.867)*

0.667 (0.507 to 0.879)*

0.632 (0.406 to 0.984)*

16≤HRR≤22 (n=373)

OR (95% CI) by Quintile of HRR

0.568 (0.425 to 0.759)#

0.620 (0.468 to 0.821)*

0.439 (0.305 to 0.796)#

HRR≥23 (n=348)

P for

<0.001

<0.001

<0.001

Trend

Notes: Data are presented as Odds ratio (95% CI). *P<0.05, #P<0.001, assessed by multivariate logistic regression models adjusted for age, sex, race, BMI, smoking status, and CVD history. P for trend were estimated by logistic
regression models including the median of each quartile as a continuous variable.
Abbreviations: HRR, heart rate recovery; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnoea scale; OR, odds ratio.

0.986 (0.979 to 0.993)

#

0.987 (0.976 to 0.998)*

a Continuous Variable

mMRC ≥ 2

Exacerbation frequency ≥ 2

Dependent Variables

Table 4 Associations Between Severe Symptoms and Frequent Exacerbator Status and Heart Rate Recovery (HRR, bt/min) in Patients with COPD

Notes: Data are presented as Mean difference (95% CI). The emphysema percentage, and gas trapping percentage were natural log transformed because of their skewed distributions. *P<0.05, #P<0.001, assessed by multivariate
generalized linear regression models adjusted for age, sex, race, BMI, smoking status, CVD history, and CT scanner type for CT outcomes. β = standardized coefficient represents the change of the dependent variable for 1 bt/min change
in HRR. P for trend were estimated by generalized linear models including the median of each quartile as a continuous variable.
Abbreviations: HRR, heart rate recovery; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide; DLCO%pred, percentage of predicted DLCO, adjusted for
haemoglobin concentration and altitude; CT, computed tomography; Pi10, square root wall area of a 10-mm perimeter airway; WA, segmental wall area percentage; AWT, segmental airway wall thickness; PRISm, Preserved Ratio Impaired
Spirometry defined as FEV1/FVC ≥ 70% but FEV1 < 80%.

0 (ref)

0 (ref)

0 (ref)

0.043 (0.008 to 0.079)*

FVC%pred (%)
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Figure 2 Odds ratio of COPD severity based on abnormal heart rate recovery (HRR≤10 bt/min). Multivariable logistic regression model for patients with COPD (n=2127)
at baseline, adjusting for age, sex, race, BMI and smoking status. (A) Associations between abnormal HRR and severe symptoms. (B) Associations between abnormal HRR
and COPD severity grades.
Abbreviations: HRR, heart rate recovery; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnoea scale; GOLD, Global Initiative for Chronic
Obstructive Lung Disease.

patients with HRR≥11 bt/min, those with HRR≤10 bt/min
had significantly (P<0.01): Worse pulmonary function;
worse 6MWT physiology (including lower 6MWD,
greater pre-walk-HR, lower end-walk-HR, and less recov
ery of SpO2); worse emphysema and airway morphology
on chest CT; more severe COPD symptoms; greater
exacerbation frequency; and greater combination of
inhaled long-acting beta-agonist, inhaled long-acting mus
carinic antagonist and inhaled corticosteroid use (Table 6).

Discussion
This is the first study to show that HRR≤10 bt/min after
6MWT in COPD patients was an important cut-off which
was significantly associated with impaired 6MWT dis
tance, spirometry and DLCO and CT variables of airway
morphology. This is also the first study to show that low
Table 5 Risk Ratio (RR) for Exacerbations in the Year Prior to
5-Year Follow-Up in 385 Patients with COPD Heart Rate
Recovery (HRR) ≤10 bt/min Compared to Those with HRR
≥11 bt/min (Reference)
Variable

RR

95% CI

P value

Crude

1.759

1.121–2.758

0.014

Model 1

1.747

1.111–2.745

0.016

Model 2
Model 3

1.762
1.775

1.118–2.775
1.126–2.798

0.015
0.014

Model 4

1.823

1.148–2.894

0.011

Model 5

1.827

1.071–3.115

0.027

Notes: Logistic regression model for COPD patients followed-up for 5-years
(n=385). Crude: Single factor for logistic regression. Model 1: Adjusted for sex.
Model 2: Adjusted for sex, age. Model 3: Adjusted for sex, age, body mass index
(BMI). Model 4: Adjusted for sex, age, body mass index (BMI), race, smoking status,
CVD. Model 5: Adjusted for sex, age, body mass index (BMI), race, smoking status,
CVD, FEV1%pred, DLCO%pred, 6MWD.

2554

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/COPD.S311572

DovePress

HRR was independently associated with airway wall
thickening in smokers with or without COPD, suggesting
airway morphologic changes may influence autonomic
function. Using HRR≤10 bt/min cut-off, we showed
increased odds in COPD patients of worse dyspnoea and
quality of life and increased exacerbation frequency. In
addition, in a subgroup of 385 COPD patients, we also
showed that HRR≤10 bt/min was a significant predictor of
exacerbations during the year preceding the 5 year followup visit. HRR≤10 bt/min at 1-minute after a 6MWT in
COPD is, therefore, proposed as an important tool to
evaluate the clinical manifestation of severe outcomes in
COPD.
Seshadri et al (2004) were the first to characterize HRR
in COPD patients. In 627 participants, they found that
HRR≤12 bt/min after incremental exercise testing in smo
kers and non-smokers was associated with spirometric
abnormalities, such as lower FEV1%pred.8 This was cor
roborated by Gupta et al (2013), who found that COPD
patients with HRR≤12 bt/min after target-HR-limited or
symptom-limited incremental cycle ergometry had lower
FEV1%pred than those with HRR≥13 bt/min, and that
abnormal HRR increased in frequency together with
GOLD-defined COPD severity.9 Both studies used the
HRR≤12 bt/min criterion established by Cole et al
(1999) who - from a prospective cohort referred for exer
cise testing - showed that this cut-off associated with
mortality in cardiovascular disease patients.5 It was sug
gested that autonomic dysfunction (reflected in elevated
heart rate, reduced baroreflex sensitivity, reduced heart rate
variability and/or prolonged QTc interval) would also
result in low HRR following exercise.29 However, the
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Table 6 Characteristics of Patients with COPD Stratified by a Criterion Heart Rate Recovery (HRR) After 6MWT of 10 bt/min
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Variables

COPD with Abnormal HRR
≤10 bt/min (n=1027)

COPD with Normal HRR ≥11
bt/min (n=1100)

Total (n=2127)

P value

Age (years)

67.5±8.5

67.5±8.1

67.5±8.3

0.958

Sex, Male, n (%)

570 (28.3%)

602 (26.8%)

1172 (55.1%)

0.720

BMI (kg/m2)

27.6±6.2

28.1±6.1

27.9±6.2

0.069

Race, Non-Hispanic White, n (%)

743 (34.9%)

857 (40.3%)

1600 (75.2%)

0.003

Ex-smoker

631 (29.7%)

707 (33.2%)

1338 (62.9%)

0.177

Current smoker

396 (18.6%)

393 (18.5%)

789 (37.1%)

0.177

Smoking (pack-years)

51±26

49±24

50±25

0.107

6MWD (m)

350.3±118.7

396.6±122.8

374.3±123.0

<0.001

HR pre-walk (bt/min)

76±13

73±12

75±13

<0.001

SpO2 pre-walk (%)

95.0±3.7

95.6±3.1

95.3±3.4

0.001

HR end-walk (bt/min)

91±17

104±17

98±18

<0.001

HR 1-min post (bt/min)

87±16

83±15

85±16

<0.001

SpO2 end-walk (%)

91.9±6.0

92.1±6.0

92.0±6.0

0.531

SpO2 1-min post (%)

94.6±4.6

95.5±3.9

95.1±4.2

<0.001

Post-BD FEV1%pred (%)

59.7±22.5

64.1±22.4

62.0±22.6

<0.001

Post-BD FVC%pred (%)

81.9±19.5

85.4±19.8

83.7±19.7

<0.001

Post-BD FEV1/FVC (%)

53.8±12.7

55.5±11.7

54.7±12.3

0.001

DLCO%pred (%)

62.6±22.1

66.1±21.5

64.4±21.9

0.001

Emphysema (%)

5.9 (1.9–16.6)

5.0 (1.6–14.5)

5.4 (1.7–15.3)

0.008

Gas trapping (%)

31.1 (18.3–51.5)

29.6 (15.8–46.3)

30.4 (16.9–49.2)

0.005

Pi10 (mm)

2.6±0.6

2.5±0.6

2.5±0.6

0.035

WA (%)

53.6±8.3

52.6±8.2

53.1±8.2

0.011

AWT (mm)

1.11±0.24

1.07±0.22

1.09±0.23

0.001

Demographics

Smoking status, n (%)

6-min walk test

Pulmonary function

Quantitative chest CT

COPD assessment
Exacerbations/year

0 (0–1)

0 (0–0)

0 (0–1)

0.036

Exacerbation frequency ≥2, n (%)

139 (6.5%)

92 (4.3%)

231 (10.9%)

<0.001

mMRC

2 (0–3)

1 (0–3)

2 (0–3)

<0.001

CAT

15 (8–22)

12 (7–19)

13 (7–20)

<0.001

CAT ≥10, n (%)

716 (33.7%)

677 (31.8%)

1393 (65.5%)

<0.001

mMRC ≥2, n (%)

569 (26.8%)

514 (24.2%)

1083 (50.9%)

<0.001

Non-medication

336 (15.8%)

453 (21.3%)

789 (37.1%)

<0.001

LABA use

11 (0.5%)

8 (0.4%)

19 (0.9%)

0.400

LAMA use

99 (4.7%)

88 (4.1%)

187 (8.8%)

0.182

LABA+LAMA use

18 (0.8%)

20 (0.9%)

38 (1.8%)

0.909

ICS+LABA or LAMA use

168 (7.9%)

164 (7.7%)

332 (15.6%)

0.357

LABA+LAMA+ ICS use

206 (9.7%)

177 (8.3%)

383 (18.0%)

0.017

Others

189 (8.9%)

190 (8.9%)

379 (17.8%)

0.496

Medication, n (%)

Note: Data are presented as mean±SD or median (interquartile range), or number (percent).
Abbreviations: HRR, heart rate recovery; BMI, body mass index; SpO2, oxygen saturation by pulse oximeter; 6MWD, 6-minute-walk distance; BD, bronchodilator; FEV1,
forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide; DLCO%pred, percentage of predicted DLCO,
adjusted for haemoglobin concentration and altitude; CT, computed tomography; Pi10, square root wall area of a 10-mm perimeter airway; WA%, segmental wall area
percentage; AWT, segmental airway wall thickness; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnoea scale; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; LABA, inhaled long-acting beta-agonist; LAMA, inhaled long-acting muscarinic antagonist; ICS, inhaled corticosteroid.
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HRR≤12 bt/min criterion value may not be suitable after
6MWT in COPD patients, who commonly reach symptom
limitation before reaching cardiovascular limitation during
exercise.30 Lower peak HR during exercise would predis
pose towards smaller HRR. Indeed, our data show in
COPD patients stratified on HRR≤10 bt/min (Table 6),
that pre-walk HR is significantly higher (by 3 bt/min)
and end-walk HR is significantly lower (by 15 bt/min)
than those with HRR≥11 bt/min. These patients also had
worse spirometry, DLCO, airway wall thickening and
symptom and exacerbation burden. This is consistent
with the notion that more severe COPD patients are less
able to increase HR during 6MWT and, therefore, less able
to recover by ≥11 bt/min. We suggest that HRR≤10 bt/min
can be used to identify COPD patients at greater risk for
worse dyspnoea, quality of life and future exacerbations.
COPD is characterized by poorly-reversible expiratory
airflow limitation, caused by emphysema and/or airway
remodeling.31,32 Airway wall thickening and emphysema
provide independent contributions to expiratory flow lim
itation and gas exchange impairment in COPD.26 Lower
FEV1 is associated with both greater airway wall
thickness33,34 and with emphysema and gas trapping.35,36
We used CT to assess airway remodeling33 and
emphysema37 in relation to 6MWT performance and
HRR. We measured wall area percentage, airway wall
thickness and Pi10, which collectively reflect wall thicken
ing across the entire bronchial tree and negatively associ
ate with FEV1.35 We demonstrated that wall area
percentage, airway wall thickness and Pi10, but not mea
sures of emphysema, decreased progressively with
increasing HRR, and were independently negatively asso
ciated with HRR≤10 bt/min in smokers with or without
COPD. As emphysema and impaired DLCO are more
strongly associated with exercise-induced arterial hypox
emia, it might be hypothesized that HRR recovery would
be more impaired in those with greater gas exchange
abnormalities.38 In accordance with this suggestion,
DLCO was negatively associated with HRR, but we found
no relation between HRR and emphysema on CT. In
addition, although 1515 (30.3%) participants experienced
at least mild exercise induced arterial desaturation (SpO2
<92%), this was only very weakly associated with HRR
(β=0.016, 95% CI 0.005–0.027, r2=0.002) (c.f.39). Our
results are therefore consistent with a greater autonomic
disturbance in airway predominant disease rather than in
emphysema.
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Vagal afferent innervation of the respiratory tract is thought
to be activated in COPD by alterations in airway mechanical
stimuli, inflammatory and noxious sensory stimuli,16,17
increasing bronchoconstriction and susceptibility to cough.
Similarly, sympathetic activity is enhanced in COPD patients,
and is known to be affected by several mechanisms associated
with COPD, including: Recurrent hypoxemia; hypercapnia;
increased intrathoracic pressure alterations; respiratory effort;
systemic inflammation; pulmonary circulation; and use of
beta-sympathomimetics resulting in augmented cardiac after
load. Indeed, anticholinergic bronchodilators reduce HRR
after exercise in COPD patients,40 and we found greater com
bination of LABA, LAMA and inhaled corticosteroids use in
those with abnormal HRR. However, although patients did not
temporarily abstain from long-acting bronchodilator medica
tions for this study, the 6MWT was conducted after albuterol
administration for spirometry assessment in all participants,
meaning beta-agonist load should have been high in all sub
jects. In addition, chronic inflammation is associated with
autonomic dysfunction in middle-aged and elderly subjects
with no apparent heart disease.41 Taken together, our findings
support that chronic inflammation and/or an association
between bronchial and cardiac vagal tone are reflected in an
association between airway wall thickness and abnormal HRR
in COPD patients. Therefore, HRR≤10 bt/min cut-off might
provide a prognostic feature of airway-dominant COPD.42
Further study is warranted to identify mechanisms involved
in associations among HRR, parasympathetic nervous activity
and airway wall thickness in COPD. Indeed, the association
between HRR and airway abnormalities remains even when
diagnostic criteria (eg COPD or non-COPD) are considered.
This suggests that HRR may represent a treatable trait,43
mediated by an underlying airway and/or autonomic patho
physiology, that could be a target to improve outcomes agnos
tic of diagnostic phenotype.
The GOLD ABCD assessment tool20,44 identifies high
est risk COPD patients using exacerbation frequency ≥2 in
the previous year, combined with significant dyspnoea
assessed by CAT ≥10 or mMRC ≥2. GOLD D patients
have the worst health status and outcomes.20 To our
knowledge, this is the first study to show that HRR≤10
bt/min was independently associated with GOLD D COPD
classification. COPD patients with HRR≤10 bt/min have
greater risk for symptoms and frequent exacerbations than
those with HRR≥11 bt/min. We also demonstrated that
HRR≤10 bt/min was a predictor for future exacerbation
at 5-year follow-up in 385 COPD patients.
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Previous studies have associated HRR≤14 bt/min with
future exacerbation risk15 or mortality in COPD.7 These
studies, however, found no association between HRR and
pulmonary function or symptoms. HRR≤10 bt/min after
6MWT, on the other hand, identified associations with
both COPD severity and future exacerbation. This, again,
supports the notion that HRR≤10 bt/min after 6MWT may
further inform COPD prognosis.
Our study has several limitations. Firstly, we do not
have mortality data to assess association with HRR at
different cut-off values. At the time of writing, only
a modest fraction of COPDGene participants have been
followed up at their 10-year visit (phase 3), introducing
potential for selection bias in our exacerbation outcome
data. There also remains chance bias due to the multi
ple outcomes examined. Secondly, common medica
tions such as β-agonists may alter the HR and HRR
response to 6MWT. However, the type and amount of
medication use is a Co-variate of COPD severity;
therefore, adjusting for medication confounds analyses
for associations between HRR and COPD severity. We
also sought to adjust for peak HR in our models.
Adjustment of peak HR tended to increase the strength
of association between HRR and some model variables,
eg the association between HRR and FEV1%pred
increased from β=0.194 to β=0.318 (P<0.001 for
both). However, peak HR is used in the calculation of
HRR, and its inclusion introduced variance of the
coefficients without major impact on the primary
study conclusions. For this reason, peak HR was not
included in the presented models. In addition, exacer
bations in the previous year are known to be the pri
mary predictor of subsequent exacerbations. Since we
did not measure exacerbations prior to our follow-up
window, we are not able to assess the independence of
HRR as a predictor of exacerbations at 5-year follow
up. Finally, patients with HRR≤10 bt/min are also
included in groups with greater cut-off values (eg,
≤12–16 bt/min), which introduces bias when attempt
ing to identify which cut-off value to use. Here we
chose to report the lowest value, because COPD is
predisposed to lower end-walk HR values than some
other patient populations. Although not shown, using
≤12, ≤14 or ≤16 bt/min as more granular criteria cutoff values, did not change the main finding that
HRR≤10 bt/min was the lowest HRR criterion identify
ing severe impairments in clinical outcomes.
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Conclusions
In conclusion, in this retrospective study we demonstrated
that HRR≤10 bt/min after 6MWT in COPD was associated
with: 1) worse lung function and airway wall thickening; 2)
worse dyspnoea and quality of life; and 3) greater exacer
bation burden; and was 4) prognostic of future exacerba
tions. These findings suggest that HRR of ≤10 bt/min may
be useful as part of a comprehensive longitudinal assess
ment in COPD patients to determine risk for disease
severity, symptoms and future exacerbations.
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